Cell line · CVCL_1562
NCI-H446
Cancer cell line, Homo sapiens. Lung small cell carcinoma. 59 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H446. Cell lines, record CVCL_1562. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1562
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H446
- Accession
- CVCL_1562
- RRID
- RRID:CVCL_1562
- Synonyms
- H446, H-446, NCI-446, NCIH446
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 61Y
- Category
- Cancer cell line
- Diseases
- Lung small cell carcinoma (NCIt C4917); Small cell lung cancer (ORDO Orphanet_70573)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers59
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| NK cell immune fitness stratifies small cell lung cancer into four functional states associated with clinical response. | J Liq Biopsy | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer. | Transl Lung Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TNIK Overexpression Is Sufficient for Chemoradiation Resistance in Limited-Stage Small Cell Lung Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A public data-based molecular classification of small cell lung cancer by neuroactive signaling networks unveils distinct microenvironment landscapes and immunotherapy-related prognostic biomarkers. | Transl Lung Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Sympathetic Neurons Promote Small Cell Lung Cancer through the β2-Adrenergic Receptor. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 59
See all 59 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | H446/CDDP | CVCL_RT21 | Cell lines | |
| Derived from it | H446/EP | CVCL_RT18 | Cell lines | |
| Derived from it | H446/VP | CVCL_C1MD | Cell lines | |
| Derived from it | HyCyte NCI-H446 hHFE_p.C282Y_c.845G>A | CVCL_E2Q8 | Cell lines |
Cell banks4
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-171 | ATCC | |
| CLS | 305049 | CLS | |
| Hysigen | TCH-C285 | Hysigen | |
| KCB | KCB 200688YJ | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1562
GET https://conductscience.org/api/cell-lines/v1/CVCL_1562/papers?page=2